When did CRISPR Therapeutics report Q4 2024 earnings?

CRISPR Therapeutics (CRSP) reported Q4 2024 earnings on February 11, 2025 before market open.

What were CRISPR Therapeutics's Q4 2024 revenue and EPS?

CRISPR Therapeutics reported revenue of $35.0M and diluted EPS of $-0.44 for Q4 2024.

Did CRISPR Therapeutics beat estimates in Q4 2024?

Revenue beat the consensus estimate of $8.1M by $26.9M. EPS beat the consensus estimate of $-1.15 by $0.71.

Where can I find CRISPR Therapeutics's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-017899) directly on SEC EDGAR. The filing index links above go to sec.gov.

CRISPR Therapeutics CRSP Q4 2024 Annual earnings

Reported February 11, 2025 · Before market open

Revenue$35.0MBeat by $26.9M Diluted EPS-$0.44Beat by $0.71

Revenue estimate$8.1M

EPS estimate-$1.15

Next report

Aug 3, 2026 (In 3 weeks)

Revenue estimate$7.4M

EPS estimate-$1.20

Financials

Q4 2024

Income statement

See full

Revenue$35.7M-82.3%

Operating income-$64.6M—

Net income-$37.3M—

EPS (diluted)-$0.42—

Balance sheet

See full

Cash & equivalents$298.3M-23.4%

Total debt$223.7M-6.3%

Total equity$1.9B+2.6%

Total assets$2.2B+0.6%

Cash flow

See full

Operating cash flow-$50.0M+47.9%

CapEx$254.0K-65.6%

Free cash flow-$50.3M+48.1%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$3.36B-32.4%

Enterprise value$3.28B-31.9%

P/S90×+76.6×

Profitability

See full

Operating margin-1,250.4%—

Net margin-981.5%—

FCF margin-387.7%-504pp

Returns & leverage

See full

Return on equity-19.2%—

Debt / equity0.1×0.0×

Current ratio22.1×+4.5×

Segments

By product

See full

Collaboration Revenue$35.0M-82.5%

Grant$691.0K-42.7%

Versus estimates

Revenue

Q1 2026$1.5MMiss by $4.6M Q4 2025$864.0KMiss by $3.9M Q3 2025$889.0KMiss by $8.2M Q2 2025$892.0KMiss by $8.5M Q1 2025$865.0KMiss by $5.1M

Q4 2024$35.0MBeat by $26.9M

Diluted EPS

Q1 2026-$1.28Miss by $0.08 Q4 2025-$1.37Miss by $0.22 Q3 2025-$1.17Beat by $0.09 Q2 2025-$1.29Beat by $0.18 Q1 2025-$1.58Miss by $0.31

Q4 2024-$0.44Beat by $0.71

Ask the moment CRISPR Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did CRISPR Therapeutics report Q4 2024 earnings?: CRISPR Therapeutics (CRSP) reported Q4 2024 earnings on February 11, 2025 before market open.
What were CRISPR Therapeutics's Q4 2024 revenue and EPS?: CRISPR Therapeutics reported revenue of $35.0M and diluted EPS of $-0.44 for Q4 2024.
Did CRISPR Therapeutics beat estimates in Q4 2024?: Revenue beat the consensus estimate of $8.1M by $26.9M. EPS beat the consensus estimate of $-1.15 by $0.71.
Where can I find CRISPR Therapeutics's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-017899) directly on SEC EDGAR. The filing index links above go to sec.gov.